Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering

Helus Pharma, a company focused on developing new treatments for mental health conditions, has successfully completed a $50 million underwritten share offering, which will likely bolster its research and development efforts. This move is crucial as it positions the company to further its pipeline of serotonergic agonists, potentially offering new therapeutic options for mental health issues. The capital influx underscores investor confidence in the innovative approach Helus Pharma is taking to address unmet needs in mental health treatment.